20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Janux Therapeutics Inc (JANX) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 113 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, JANX reported $10M in revenue and ($114M) in net income.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
Interactive charts & full statements → Open the JANX valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $32M | $10M | $11M | $8M | $9M | $4M | $0M | $0M |
| Gross Profit | $22M | $8M | $9M | $6M | $9M | $4M | $0M | $0M |
| Gross Margin % | 68.9% | 79.7% | 80.5% | 75.8% | 100.0% | 100.0% | -3.4% | — |
| Operating Income (EBIT) | ($144M) | ($158M) | ($99M) | ($73M) | ($67M) | ($33M) | ($5M) | ($4M) |
| Operating Margin % | -450.3% | -1576.7% | -933.6% | -902.9% | -779.0% | -905.4% | -1274.5% | — |
| Net Income | ($103M) | ($114M) | ($69M) | ($58M) | ($54M) | ($33M) | ($7M) | ($4M) |
| Net Margin % | -321.8% | -1136.2% | -651.6% | -721.2% | -628.8% | -895.2% | -1785.3% | — |
| EBITDA | ($101M) | ($112M) | ($67M) | ($56M) | ($66M) | ($33M) | ($7M) | ($4M) |
| Earnings Per Share (EPS) | $-1.65 | $-1.83 | $-1.28 | $-1.32 | $-1.31 | $-0.79 | $-0.16 | $-0.10 |
| Shares Outstanding (M) | 63M | 62M | 54M | 44M | 41M | 41M | 42M | 42M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $10M | $4M | $8M | $10M | $0M | $0M | ($9M) | $0M |
| Gross Profit | $10M | $3M | ($1M) | $9M | ($29M) | ($25M) | ($21M) | ($2M) |
| Gross Margin % | 100.0% | 87.4% | -13.5% | 95.0% | — | — | 244.4% | -440.8% |
| Operating Income (EBIT) | ($32M) | ($34M) | ($42M) | ($35M) | ($45M) | ($35M) | ($29M) | ($36M) |
| Operating Margin % | -308.7% | -916.5% | -538.1% | -352.5% | — | — | 340.9% | -8164.5% |
| Net Income | ($22M) | ($24M) | ($32M) | ($24M) | ($34M) | ($24M) | ($20M) | ($28M) |
| Net Margin % | -214.0% | -652.6% | -405.4% | -243.1% | — | — | 237.5% | -6391.6% |
| EBITDA | ($22M) | ($24M) | ($31M) | ($24M) | ($33M) | ($23M) | ($20M) | ($28M) |
| Earnings Per Share (EPS) | $-0.35 | $-0.39 | $-0.52 | $-0.39 | $-0.55 | $-0.38 | $-0.36 | $-0.51 |
| Shares Outstanding (M) | 63M | 63M | 62M | 62M | 62M | 62M | 57M | 55M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($54M) | ($82M) | ($44M) | ($51M) | ($43M) | ($17M) | ($4M) | ($4M) |
| Capital Expenditures (CapEx) | $1M | $1M | $0M | $2M | $6M | $1M | $1M | $1M |
| Free Cash Flow (FCF) | ($55M) | ($83M) | ($44M) | ($52M) | ($49M) | ($18M) | ($6M) | ($5M) |
| FCF Margin % | -171.1% | -832.8% | -417.2% | -648.6% | -573.2% | -507.5% | -1539.7% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $12M | ($12M) | ($29M) | ($13M) | ($24M) | ($17M) | ($17M) | ($2M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | $13M | ($13M) | ($29M) | ($13M) | ($24M) | ($17M) | ($17M) | ($2M) |
| FCF Margin % | 130.0% | -337.8% | -363.6% | -129.5% | — | — | 197.0% | -513.9% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.0B | $1.0B | $1.1B | $380M | $364M | $380M | $16M | $1M |
| Cash & Cash Equivalents | $28M | $52M | $431M | $19M | $51M | $36M | $8M | $1M |
| Total Liabilities | $80M | $51M | $39M | $36M | $43M | $13M | $31M | $9M |
| Total Debt (Short + Long-Term) | $3M | $2M | $2M | $2M | $1M | $0M | $1M | $4M |
| Total Shareholders' Equity | $928M | $957M | $1.0B | $344M | $321M | $366M | ($15M) | ($8M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive JANX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms